Edge Medical Devices plans to introduce a new, lower-cost flat-panel detector for digital radiography (DR) at the RSNA meeting. The company’s selenium-based SMART (Scanned Matrix Array Readout Technology) detectors use a proprietary sensor technique
Edge Medical Devices plans to introduce a new, lower-cost flat-panel detector for digital radiography (DR) at the RSNA meeting.
The companys selenium-based SMART (Scanned Matrix Array Readout Technology) detectors use a proprietary sensor technique to replace the active matrix array technology on competing flat panels, with the goal being to bring the price of DR within reach for smaller institutions.
Eliminating the active matrix array elements simplifies the manufacturing process and means Edge does not have to invest in a large-scale semiconductor fabrication facility. Edge expects to keep its flat-panel price at about half that of competing technologycloser to the cost of CR.
Flat-panel digital acquisition involves conversion of x-rays to electrical charges, said A. Robert Sohval, Edge president. Then charges are read out to form a digital image, typically using active matrix array technology.
Manufacturing arrays with several million individually addressable elements is difficult and costly, according to Sohval.
Yields are often low because of problems with dead pixels. With its new technology, Edge has eliminated the most complex phase of DR manufacturing, he said.
Another benefit is that Edge uses an amorphous selenium sensor to directly convert incident x-rays in a single step, while some manufacturers use a two-step, indirect process, according to Sohval.
Edge claims the detectors thin profile will allow it to replace the film-screen bucky in a standard chest stand or radiographic table with only minor modifications. The company plans to offer retrofit kits to end users through a dealer network and to supply detectors to OEMs for use in new DR systems.
We believe our new technology will be attractive even to OEMs already in DR, in part because of the streamlined production process. Additionally, its price point opens up a whole new category of potential customers, Sohval said.
The company plans to submit its technology for FDA clearance in the first quarter of 2001 and to commence deliveries in the second quarter.
Edge was founded in Israel. Its U.S. headquarters are in Hackensack, NJ.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.